Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase 2/3 Trial of Vincristine-Irinotecan-Regorafenib in Combination With Vincristine-Doxorubicin-Cyclophosphamide (VDC) and Ifosfamide-Etoposide (IE) in Patients With Newly Diagnosed Metastatic Ewing Sarcoma

NCT06820957 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT06820957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06820957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase 2/3 Trial of Vincristine-Irinotecan-Regorafenib in Combination With Vincristine-Doxorubicin-Cyclophosphamide (VDC) and Ifosfamide-Etoposide (IE) in Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Lead sponsor
Children's Oncology Group
Phase
Phase 2/3
Overall status
Terminated
Start date
November 10, 2025
Completion date
September 22, 2026
Enrollment
2 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

cic-rearranged sarcoma, metastatic ewing sarcoma, metastatic high grade sarcoma, metastatic undifferentiated round cell sarcoma, metastatic undifferentiated sarcoma, not otherwise specified, round cell sarcoma with ewsr1-non-ets fusion, sarcoma with bcor genetic alterations